Boston Scientific Corporation (NYSE: BSX) is re-evaluating its 2027 financial framework in light of a recent cybersecurity incident. The company also announced it is executing a significant restructuring plan intended to provide financial benefits.

An executive stated that the firm will provide a preview of the updated outlook in October. This development follows the company's warning that it is unlikely to meet its previously issued net sales growth and adjusted earnings per share guidance for the third quarter and full fiscal year 2026.

Operational Impact

The disclosure follows a cybersecurity incident identified on August 25, 2026, which caused a global disruption to the company’s operations. The company filed a Current Report on Form 8-K with the Securities and Exchange Commission on August 26, 2026, detailing the breach.

The incident involved unauthorized activity on certain information technology systems, resulting in a network outage that affected access to operating systems and business applications. This disruption impacted the company’s ability to manufacture products as well as process and ship customer orders.

As of the date of the report, the company has not identified evidence of ongoing unauthorized access. However, the investigation remains ongoing with the assistance of third-party cybersecurity experts.

Recovery Progress

Boston Scientific reported progress in restoring affected systems. Key developments include:

• Substantial restoration of its distribution network.
• Major distribution centers now processing and shipping customer orders at or above normal operating levels.
• Sterilization facilities are operational.
• Manufacturing has resumed across most facilities globally.

The timeline for a full operational recovery remains uncertain. The company anticipates recovering some portion of the impacted revenue as it continues to ramp operations globally, fulfill customer orders, and reduce remaining backlogs. However, the full financial impacts are not yet known.

Financial Outlook

Based on currently available information, the company determined that the incident is likely to have a material impact on its results of operations for the third quarter and full year 2026. Consequently, it expects to miss the guidance ranges provided on July 29, 2026.

On July 29, Boston Scientific guided third-quarter net sales growth of approximately 3%-5% on a reported and organic basis, equivalent to sales of $5.217 billion-$5.318 billion, versus a consensus of $5.358 billion. It had also guided to adjusted earnings of 80-82 cents, against a consensus of 83 cents. The company now says it is unlikely to reach either range.

Despite the near-term operational and financial headwinds, Boston Scientific stated that it does not expect the incident to have a material impact on its long-term financial condition.

Market Reaction

Boston Scientific shares were down 5.31% at $45.26 on Tuesday, according to Benzinga Pro data.

The company intends to provide an update on its operational and financial outlook for the remainder of fiscal year 2026 during its planned conference call to discuss financial results and business highlights for the third quarter 2026. This call is scheduled for Wednesday, October 28, 2026.

Boston Scientific Corp. (NYSE: BSX) faces a Class I recall for its Infinion CX Spinal Cord Stimulator leads after the FDA flagged severe patient harm risks.

The regulatory advisory, released on Thursday, mandates the immediate withdrawal of all unused inventory from point-of-sale and operational locations. This represents the most serious category of device recall available under US regulations.

Scope of Recall and Patient Impact

The recall applies exclusively to un-implanted inventory. Facilities must halt distribution, isolate remaining stocks, and return them directly to Boston Scientific. Healthcare providers are required to notify internal staff and external clinical entities that received transferred items.

Patients with currently implanted devices do not require supplementary medical surveillance beyond standard clinical follow-up care. The company confirmed that no patient deaths have been reported in connection with the issue.

Device Failure Mechanism

The defect stems from mechanical stress along the anchor site of the lead body within the Spinal Cord Stimulator System. This strain can induce lead fractures or create excessively high impedance measurements.

Abnormal impedance readings may result in insufficient pain management therapy or necessitate secondary operative procedures, including complete lead explant and surgical replacement.

Injury Data and Market Reaction

As of May 27, 2026, Boston Scientific documented 1,081 serious injuries tied to these physical defects. Despite the volume of reported injuries, the enterprise confirmed zero associated fatalities.

Boston Scientific shares were up 1.77% to $47.78 at the time of publication on Friday, according to Benzinga Pro data.

What the Numbers Show

The divergence between the high count of serious injuries (1,081) and the absence of reported deaths suggests that while device failure rates are significant, clinical outcomes have thus far avoided mortality. However, the potential for secondary surgeries indicates ongoing operational risk for patients with implanted units, even as the immediate recall targets only un-implanted stock.